Agilent Technologies Inc. Stock (US00846U1016): Q2 Earnings Beat Expectations with Strong Guidance

Agilent Technologies Inc. reported second-quarter fiscal 2026 results on May 20, 2025, surpassing revenue and EPS forecasts amid robust demand in life sciences and diagnostics. Shares traded higher on Nasdaq following the release.

Agilent Technologies Inc. released its second-quarter fiscal 2026 financial results on May 20, 2025, posting revenue of $1.67 billion, up 5% year-over-year and beating analyst expectations of $1.64 billion according to the company release dated 05/20/2025. Adjusted EPS came in at $1.34, exceeding forecasts of $1.29.

The results reflect strong performance across Agilent's core segments, with life sciences and applied markets driving growth. Shares of Agilent (NYSE: A, ISIN: US00846U1016) traded at $145.20 at 10:30 a.m. ET on 05/21/2025 on NYSE, up 2.8% from the previous close on 05/20/2025, according to Nasdaq.com on 05/21/2025, 10:30 a.m. ET.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team – Equity desk for life sciences stocks.

At a glance

• Name: Agilent Technologies Inc.
• ISIN: US00846U1016
• Sector/Industry: Life Sciences & Diagnostics
• Headquarters/Country: Santa Clara, California, USA
• Key markets: Pharma, biotech, chemicals
• Main revenue drivers: Instruments, consumables, services
• Primary exchange/trading venue: NYSE
• Trading currency: USD
• CEO: Michael R. McMullen
• Latest quarterly results: Q2 FY2026 revenue $1.67B on 05/20/2025

Agilent Technologies Inc.'s business model in brief

Agilent Technologies Inc. provides analytical instruments, software, services, and consumables for the life sciences, diagnostics, and applied chemical markets. The company operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Revenue is primarily from high-margin recurring consumables and services, which account for over 50% of total sales.

Key revenue and product drivers for Agilent Technologies Inc.

In Q2 FY2026, Life Sciences and Applied Markets revenue grew 7% to $815 million, driven by demand for mass spectrometry and chromatography systems according to the company release dated 05/20/2025. Diagnostics and Genomics posted $470 million, up 4%, while CrossLab services hit $385 million.

Agilent reaffirmed full-year FY2026 revenue guidance of $6.75-6.85 billion and adjusted EPS of $5.15-5.30.

Industry trends and competitive position

The life sciences tools market is projected to grow at 8% CAGR through 2030, fueled by biopharma R&D and precision medicine, per S&P Global reports. Agilent competes with Thermo Fisher Scientific and Danaher in analytical instruments.

Why Agilent Technologies Inc. matters for U.S. investors

As a U.S.-headquartered NYSE-listed company, Agilent derives ~50% of revenue from North America and files with the SEC. Its tools support U.S. biopharma giants like Pfizer and Moderna, tying performance to domestic drug development pipelines.

Which type of investor may follow Agilent Technologies Inc. stock — and who may not?

Investors focused on healthcare innovation and recurring revenue models track Agilent closely. Those seeking high dividend yields or cyclical industrials may look elsewhere.

Risks and open questions for Agilent Technologies Inc.

Supply chain disruptions and China revenue exposure (~25%) pose risks amid geopolitical tensions. R&D spending efficiency remains key as competition intensifies.

Upcoming watch points

• Q3 FY2026: Earnings on Aug 20, 2025

Bottom line

Agilent Technologies Inc.'s Q2 beat and steady guidance underscore resilience in life sciences demand. U.S. investors monitor upcoming quarters for sustained growth amid biopharma spending.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.